Global Bispecific Antibody Market is expected to estimate USD 11 Billion by 2026.
Major Payers : Adimab, Innovent Biologics, Inc., Affimed GmbH, Amgen Inc., AstraZeneca, , Sanofi, F. Hoffmann-La Roche Ltd, Regeneron Pharmaceuticals Inc., Eli Lilly and Company, Xencor, Pieris Pharmaceuticals, Inc., Mereo BioPharma Group plc., Sobi, TG Therapeutics, Inc., Merus, MacroGenics, Inc.,
July 2020, Adimab, LLC, announced that it has launched Adagio Therapeutics Inc., a new biotechnology company that will develop a portfolio of anti-coronavirus antibodies as both therapeutics and prophylactics against COVID-19 and future coronaviruses. The Adimab team developed and optimized antibodies that are broadly protective against SARS-CoV-2, SARS-CoV-1 and two additional circulating bat coronaviruses scientists are actively monitoring.
Nov 2020, Innovent Biologics, Inc., announced that the result of the phase 1 study of monoclonal antibody in mono therapy for advanced malignancies were presented in the form of ePOSTER at the 35 th annual meeting of Society for immunotherapy off cancer.
Regeneron Pharmaceuticals, Scientists test a 'bispecific' antibody that helps T cells zero in on treatment-resistant cancers. The company has garnered a spotlight for its development of REGN-EB3, a triple antibody cocktail, which outperformed other investigational treatments last year for Ebola. The drug is under review by the U.S. Food and Drug Administration and is expected to receive full approval later this year. Regeneron scientists are also conducting research on an antibody-based medication that can prevent or treat COVID-19, depending on the patient's need.
Bispecific antibodies have emerged as a leading drug class for cancer therapy and are becoming increasingly of interest for therapeutic applications. As of April 2020, over 12 BsAbs are under clinical evaluation for use in oncology. The majority of BsAbs under clinical evaluation can be categorized as bispecific immune cell engager whereas a second less well-discussed subclass of BsAbs targets two tumor-associated antigens.
Global Bispecific Antibody market is segmented on the basis of type, application and regional. Based upon type, bispecific antibody market is classified into catumaxomab, blinatumomab, duligotumab and SAR 156597. Based upon application, the market is classified into BSMAB for diagnosis of infectious diseases, diagnosis of bacterial infections, diagnosis of viral infections, BSMAB for cancer diagnostic, BsAbs blocking signaling pathways, BSABS targeting tumor angiogenesis. By regions market covered in this Global bispecific antibody market report are North America, Europe, Asia-Pacific and Rest of the World. North America has largest market in Bispecific Antibody market. In this region large number of treatment has recorded due to the high technology in biopharmaceutical industry.
Also it has observed that the highest numbers of various cancers (lung cancer, prostate cancer, breast cancer and cervical cancer) diagnosis cases are recorded from North America and Europe every year. In addition, favorable initiatives taken by the federal government also would be accounted for the market growth of bispecific antibodies treatment in North American and European regions. Further Asia-Pacific is growing their industry in antibody market but as an untapped market in bispecific antibodies treatment due to lack of proper healthcare facilities in some Asian countries.
For more information contact @